Parmentier C, et al. - Given the efficiency of rituximab (RTX) in steroid-dependent nephrotic syndrome (SDNS) in pediatric and adult patients, researchers undertook this inquiry to define hypogammaglobulinemia as a side effect of RTX therapy. They analyzed 107 pediatric patients (< 18 years old), recruited from four French pediatric nephrology centers, who were treated with RTX for SDNS between 2010 and 2015. Hypogammaglobulinemia was present in 21 patients prior to the start of RTX. Younger age at RTX start, with a median age of 8.2 years, was noted in patients who developed hypogammaglobulinemia. Findings revealed a frequent occurrence of hypogammaglobulinemia as a complication of RTX therapy in younger children managed for SDNS. Careful assessment of the use of RTX in children as well as adapting their clinical and biological follow-up to the age-dependent risk profile for hypogammaglobulinemia were recommended based on the findings.